It Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting Stent

Ju-Youn Kim, MD, Yun-Seok Choi, MD, Ami Kwon, MD, Woo-Baek Chung, MD, Chul-Soo Park, MD, Hee-Yeol Kim, MD, Kiyuk Chang, MD, Man-Young Lee, MD, Wook-Sung Chung, MD, and Ki-Bae Seung, MD

Abstract: It has been shown that triple antiplatelet therapy with cilostazol results in better clinical outcomes than dual therapy in patients treated with a first-generation drug-eluting stent (DES); however, it is unclear whether triple antiplatelet therapy has a similar efficacy after the implantation of second-generation DES.

In the COACT (CathOlic medical center percutAneous Coronary in Tervention) registry, 1248 study subjects who underwent percutaneous coronary intervention with an everolimus- or zotarolimus-eluting stent (Endeavor, Xience V, or Promus) were analyzed. The patients were divided into 2 groups after propensity score matching (n = 724; M = 422 [58.3%]; mean age = 66.1 ± 11.0 years): Group 1: patients treated with dual antiplatelet drugs (aspirin and clopidogrel; n = 362; M = 213 [58.8%]; mean age = 65.6 ± 11.7 years); Group 2: patients treated with triple antiplatelet drugs (aspirin, clopidogrel, and cilostazol; n = 362; M = 209 [57.7%]; mean age = 65.6 ± 11.7 years). The mean follow-up duration was 13 ± 10 months, and the cumulative incidence of major cardiovascular events (MACE) was 6.3% in Group 1 and 7.7% in Group 2. There were no significant differences in MACE (death, nonfatal myocardial infarction, and stroke) between the 2 groups (OR, 1.210; 95% CI: 0.772–1.898; P = 0.406). Kaplan–Meier curves for MACE did not show any survival benefit for triple antiplatelet therapy, even in patients with acute coronary syndrome.

In patients treated with a second-generation DES implantation, there is no added clinical benefit to using triple rather than dual antiplatelet therapy.

Methods

Study Population

The COACT (CathOlic medical center percutAneous Coronary inTervention) registry is a multicenter, observational registry of clinical data on patients who underwent PCI at the Catholic University of Korea between January 2004 and December 2009. A total of 1248 patients were eligible for this study. All subjects had angina pectoris or documented myocardial ischemia and an angiographically proven stenosis of ≥50% diameter. These patients received a PCI with 1 of the following second-generation DESs: Xience V everolimus-eluting stent (EES) (Abbott Vascular, Santa Clara, CA), Promus everolimus-eluting stent (EES) (Boston Scientific, Natick, MA), or Endeavor zotarolimus-eluting stent (ZES) (Medtronic Inc., Santa Rosa, CA). In addition, we did not include patients who had received repeated revascularizations, those who had previously used a first-generation DES. Study was firmly approved by Catholic Institutional Review Board. And we also got a informed consent.
Study Procedure

All patients received a loading dose of 250 to 500 mg of aspirin and 300 to 600 mg of clopidogrel before the procedure. Following the procedure, maintenance dosages of 100 mg/day of aspirin and 75 mg/day of clopidogrel were administered for at least 6 months. At the physician’s discretion, 200 mg/day of cilostazol (Otsuka Pharmaceutical, Seoul, Republic of Korea) was added and continued for at least 3 months after the PCI. Patients were placed into a dual therapy group (aspirin and clopidogrel; n = 873) or a triple therapy group (aspirin, clopidogrel, and cilostazol; n = 375). All interventions were performed in a conventional manner, and the infusion of glycoprotein IIb/IIIa inhibitors was performed according to the operator’s discretion. All patients were given unfractionated heparin during the procedure. In addition, all patients were provided with unrestricted, optimal pharmacological therapy, including statins. A successful PCI was defined as a residual stenosis of ≤30% and recovery of normal flow.

Study End Points

The primary end point was the incidence of major adverse cardiovascular events, defined as death, nonfatal myocardial infarction (MI), or stroke during the follow-up period. Death was defined as death from any cause. MI was defined as death, nonfatal MI, or stroke (OR: 0.911; 95% CI: 0.549–1.512; mean age = 65.6 ± 11.7 years). Mean duration of cilostazol was 8 ± 4 months. The propensity model included multiple factors that could influence coronary artery disease. After propensity matching, there were no significant differences in any of the covariates (Table 1).

Statistical Analysis

Baseline characteristics were summarized as the mean ± SD for continuous variables and as frequency with percentages for categorical variables. Comparisons between the 2 groups were analyzed by the Student t test or Mann–Whitney U test for continuous variables and the Chi-squared test or Fisher’s exact test for categorical variables as appropriate. To reduce the effect of selection bias and potential confounding effects in an observational study, we performed rigorous adjustments for differences in baseline patient characteristics by propensity score matching. Multivariable analysis and compared with the log-rank test for propensity score-matched pairs. All statistical tests were performed using SAS software, version 9.2 (SAS Institute Inc., Cary, NC) and were 2-sided. Results were considered significant at a P value <0.05.

RESULTS

Baseline Characteristics

The baseline characteristics of the overall populations are listed in Table 1. The prevalence of diabetes, hypertension, and a history of previous coronary artery bypass graft were significantly greater in the triple therapy group. The triple therapy group had more complex lesions, including multivessel disease, longer stent length per lesion, and left main disease. The patients were divided into the following 2 groups after propensity score matching (n = 724; M = 422 [58.3%]; mean age = 66.1 ± 11.0 years). Group 1: patients treated with dual antiplatelet drugs (aspirin and clopidogrel; n = 362; M = 213 [58.8%]; mean age = 65.6 ± 11.7 years); Group 2: patients treated with triple antiplatelet drugs (aspirin, clopidogrel, and cilostazol; n = 362; M = 209 [57.7%]; mean age = 65.6 ± 11.7 years). Mean duration of cilostazol was 8 ± 4 months. The propensity model included multiple factors that could influence coronary artery disease. After propensity matching, there were no significant differences in any of the covariates (Table 1).

Comparison of Clinical Outcomes in the Dual and Triple Therapy Groups

The mean follow-up duration was 13 ± 10 months, and the cumulative incidence of MACE was 55 (6.3%) in Group 1 and 29 (7.7%) in Group 2 (P = 0.354). There were no significant differences in MACE (death, nonfatal MI, and stroke) between the 2 groups (odds ratio [OR]: 1.210; 95% CI: 0.772–1.898; P = 0.406).

Multivariable Analysis

After multivariate adjustment, there was no difference in the risk of MACE between the 2 groups (OR: 0.987; 95% CI: 0.617–1.578; P = 0.955). In addition, the IPTW-adjusted risk of MACE did not differ between the 2 groups (OR: 1.464; 95% CI: 0.919–2.332; P = 0.109; Table 2). Similar clinical outcomes were observed in the propensity score-matched groups, with no differences in death, nonfatal MI, or stroke (OR: 0.911; 95% CI: 0.549–1.512; P = 0.719; Table 3). In addition, similar results were obtained for each of the following: death (OR: 0.720; 95% CI: 0.404–1.284; P = 0.265), recurrent nonfatal MI (OR: 3.886; 95% CI: 0.434–34.770; P = 0.225), and stroke (OR: 2.297; 95% CI: 0.594–8.881; P = 0.288). The Kaplan–Meier curves for MACE did not demonstrate any survival benefit for triple antiplatelet therapy (Figure 1).

Acute Coronary Syndrome

We performed a subgroup analysis for patients with acute coronary syndrome (n = 565; M = 354 [62.6%]; mean age = 64.7 ± 12.2 years). Patients were divided into 2 groups: Group 1 (dual therapy; n = 391; M = 245 [62.7%]; mean

Weighting (IPTW), the weights for the dual therapy group were the inverse of (1-the propensity score), and the weights for the triple therapy group were the inverse of the propensity score. Cumulative incidence rates were obtained by Kaplan–Meier analysis and compared with the log-rank test for propensity score-matched pairs. All statistical tests were performed using SAS software, version 9.2 (SAS Institute Inc., Cary, NC) and were 2-sided. Results were considered significant at a P value <0.05.
age $= 64.8 \pm 12.2$ years) and Group 2 (triple therapy; $n = 174$; $M = 109$ [62.6%]; mean age $= 64.3 \pm 12.3$ years). No significant differences were observed in the composite event rate (11.0% vs 10.3%; $P = 0.818$; Table 4). A 1:1 propensity matching analysis ($N = 322$; $M = 206$ [64.0%]; mean age $= 65.1 \pm 11.8$ years) demonstrated no difference in MACE (12.4% vs 10.6%; $P = 0.600$; OR: 0.798 [0.418–1.525], $P = 0.495$) and in TLR or TVR (6.2% vs 11.8%, $P = 0.080$; OR: 1.725 [0.801–3.717], $P = 0.164$) between the 2 groups (Figure 2).

**DISCUSSION**

The implantation of a DES is more effective and stable than a bare metal stent (BMS), which suppresses restenosis and adverse cardiac events; however, there are still unresolved clinical issues, such as very late stent thrombosis. Some stent thrombosis symptoms are fatal, especially in patients with acute coronary syndrome and/or other high-risk conditions (long stent length per lesion, small vessels, diabetes). Some studies have indicated that cilostazol-based triple antiplatelet therapy decreases MACE in these patient groups.\(^3\)\(^-\)\(^5\) To resolve these issues, researchers have begun to investigate the use of second-generation DESs; for example, novel drugs and stent materials (cobalt–chromium or platinum–chromium alloy) and biocompatible polymer undergoing laboratory and clinical tests to improve the effectiveness and safety of second-generation DESs.\(^8\)\(^-\)\(^9\) A recent meta-analysis,\(^10\) which included 22 randomized trials with 12,453 STEMI patients, compared the 1-year event rate (mortality, MI, and TVR) of BMSs, first-generation
DESs and second-generation DESs. The results showed that cobalt–chromium everolimus-eluting stents (CoCr-EES) were associated with significantly lower rates of cardiac death or MI and stent thrombosis than BMSs. In addition, first-generation DESs resulted in a significant reduction in TVR compared with BMSs; however, there were no significant differences in the risk of overall cardiac death and MI, which demonstrated the safety and efficacy of second-generation DESs.11

Based on these results, we hypothesized that there is no additive benefit when triple rather than dual antiplatelet therapy is used with a second-generation DES. To the best of our knowledge, this is the first study comparing the effectiveness of triple versus dual antiplatelet therapy using second-generation DESs. It has been reported that triple antiplatelet therapy is superior to dual antiplatelet therapy with first-generation DESs; however, even in patients with acute coronary syndrome, there was no benefit to using triple antiplatelet therapy with a second-generation DES. In the present study, patients were followed for a mean of 13 months with no evidence of a decrease in the risk of very late stent thrombosis for patients treated with triple therapy. These findings suggest that triple antiplatelet therapy is less attractive of using with second-generation stents.

### TABLE 2. Hazards Ratio for Clinical Outcomes in the Overall Population According to Antiplatelet Therapy

| Outcome (n = 1248) | Outcome Rate | Unadjusted | Multivariate Adjusted | Adjusted by IPTW |
|-------------------|--------------|------------|-----------------------|------------------|
|                   | Dual         | Triple     | HR (95% CI)           | P                |
|                   | P            |            | P                     |                  |
| MACE              | 55 (6.3)     | 29 (7.7)   | 0.35                  | 1.21 (0.77–1.90) | 0.41             |
|                   |              |            |                       | 0.99 (0.62–1.58) | 0.96             |
|                   |              |            |                       | 1.46 (0.92–2.33) | 0.11             |

CI = confidence interval, HR = hazards ratio, IPTW = inverse probability of treatment weighting, MACE = major adverse cardiac event.

### TABLE 3. Hazard Ratios for Clinical Outcomes in the Propensity-Matched Patients According to Antiplatelet Therapy

| Outcome (n = 724) | Outcome Rate | Dual | Triple | P | HR (95% CI) | P | Dual vs Triple |
|-------------------|--------------|------|--------|---|-------------|---|---------------|
|                   |              |      |        |   |             |   |               |
| MACE              | 31 (8.6)     | 29 (8.0) | 0.79 | 0.91 (0.55–1.51) | 0.72 |
| Death             | 27 (7.5)     | 20 (5.5) | 0.29 | 0.72 (0.40–1.28) | 0.27 |
| Stroke            | 3 (0.8)      | 7 (1.9)  | 0.20 | 2.30 (0.59–8.88) | 0.29 |
| Recurrent MI      | 1 (0.3)      | 4 (1.1)  | 0.18 | 3.89 (0.43–34.77) | 0.23 |

Comparisons were analyzed using Cox regression models for propensity score-matched pairs. CI = confidence interval, HR = hazards ratio, MACE = major adverse cardiac event, MI = myocardial infarction.

### TABLE 4. Hazard Ratios for Clinical Outcomes in Patients With Acute Coronary Syndrome According to Antiplatelet Therapy

| Outcome (n = 565) | Outcome Rate | Unadjusted | Multivariate Adjusted | Adjusted by IPTW |
|-------------------|--------------|------------|-----------------------|------------------|
|                   |              |            |                       |                  |
| MACE              | 43 (11.0)    | 18 (10.3)  | 0.82                  | 0.88 (0.51–1.53) | 0.66             |
|                   |              |            |                       | 0.78 (0.43–1.40) | 0.40             |
|                   |              |            |                       | 0.94 (0.52–1.69) | 0.83             |
| TLR/TVR           | 23 (5.9)     | 21 (12.1)  | 0.01<sup>1</sup>      | 1.92 (1.06–3.47) | 0.03<sup>3</sup> |
|                   |              |            |                       | 1.64 (0.85–3.17) | 0.14             |
|                   |              |            |                       | 2.39 (1.25–4.59) | 0.01<sup>3</sup> |

CI = confidence interval, HR = hazards ratio, IPTW = inverse probability of treatment weighting, MACE = major adverse cardiac event, TLR/TVR = target lesion revascularization/target vessel revascularization.

---

**FIGURE 1.** Kaplan–Meier curves for outcomes in propensity-matched patients who underwent dual antiplatelet therapy or triple antiplatelet therapy.
Study Limitations

This study was based on observational, nonrandomized trials. Therefore, there may be confounding factors, such as methodological biases and unmeasured covariates. It might be true that physician who attended in this study chose triple therapy for higher risk patients. Considering these limitations, we performed a propensity matching analysis; therefore, the number of patient groups was relatively small. So the confidence intervals of the primary endpoint are therefore quite wide.

Recruitment into this registry was spread out over a 6-year period. One could imagine that the Endeavor stent was used more frequently during the early years, and the Xience and Promus more frequently later on. Is it also possible that the annual percentage of patients treated with triple antiplatelet therapy changed over time? Clinical symptoms and objective signs were observed, collected, and analyzed. However, routine angiography follow up was only performed for a limited number of subjects during the follow-up period, making it difficult to diagnose TLR and TVR. A longitudinal randomized study with a larger number of subjects will be necessary to further investigate the use of triple versus dual antiplatelet therapy in patients treated with a second-generation DES.

CONCLUSION

In patients treated with a second-generation DES, there is no added clinical benefit to using triple rather than dual antiplatelet therapy.

Key Message

After evolving the coronary drug coated stent, the duration and number of antiplatelet therapy are going to be more simple without any additional risk even in high risk patients.

REFERENCES

1. Bonow RO, Mann DL, Zipes DP, et al. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine Philadelphia, PA: Elsevier Saunders; 2012:1349–1350.
2. Kambayashi J, Liu Y, Sun B, et al. Cilostazol as a unique antithrombotic agent. Curr Pharm DES. 2003;9:2289–2302.
3. Lee SW, Park SW, Kim YH, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eating Stent Implantation in Diabetic Patients). J Am Coll Cardiol. 2008;51:1181–1187.
4. Lee SW, Park SW, Kim YH, et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol. 2007;100:1103–1108.
5. Han Y, Li Yi, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J. 2009;157:733–739.
6. Park KW, Kang SH, Park JJ, et al. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eating Stents & Anti-platelet Regimen). JACC Cardiovasc Interv. 2013;6:932–942.
7. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584–2591.
8. Lim KS, Jeong MH, Bae IH, et al. Histopathological comparison among biolimus, zotarolimus and everolimus-eluting stents in porcine coronary restenosis model. Korean Circ J. 2013;43:744–751.
9. Ahn SG, Yoon J, Kim J, et al. Genotype- and phenotype-directed personalization of antiplatelet treatment in patients with non-ST elevation acute coronary syndromes undergoing coronary stenting. Korean Circ J. 2013;43:541–549.
10. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Clinical outcomes with drug-eluting and bare metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2013;62:496–504.
11. Babet U, Mehran R, Sharma SK, et al. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol. 2011;58:1569–1577.